


## Product datasheet

### Anti-FGFR2 antibody [EPR5180] $\alpha$ b109372

KO **VALIDATED** Recombinant RabMAb<sup>®</sup>

★★★★☆ [1 Abreviews](#) [11 References](#) [4 Images](#)

#### Overview

<b>Product name</b>	Anti-FGFR2 antibody [EPR5180]
<b>Description</b>	Rabbit monoclonal [EPR5180] to FGFR2
<b>Host species</b>	Rabbit
<b>Tested applications</b>	<b>Suitable for:</b> WB, IP <b>Unsuitable for:</b> Flow Cyt, ICC/IF or IHC-P
<b>Species reactivity</b>	<b>Reacts with:</b> Human <b>Predicted to work with:</b> Mouse, Rat 
<b>Immunogen</b>	Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.
<b>Positive control</b>	WB: MCF7, Jurkat, HeLa, K562, and T47-D cell lysates; IP: T-47D whole cell lysate.
<b>General notes</b>	<p>This product is a recombinant monoclonal antibody, which offers several advantages including:</p> <ul style="list-style-type: none"> <li>- High batch-to-batch consistency and reproducibility</li> <li>- Improved sensitivity and specificity</li> <li>- Long-term security of supply</li> <li>- Animal-free production</li> </ul> <p>For more information <a href="#">see here</a>.</p> <p>Our RabMAb<sup>®</sup> technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to <a href="#">RabMAb<sup>®</sup> patents</a>.</p>

#### Properties

<b>Form</b>	Liquid
<b>Storage instructions</b>	Shipped at 4°C. Store at -20°C. Stable for 12 months at -20°C.
<b>Storage buffer</b>	pH: 7.2 Preservative: 0.01% Sodium azide Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.5% BSA
<b>Purity</b>	Protein A purified
<b>Clonality</b>	Monoclonal
<b>Clone number</b>	EPR5180
<b>Isotype</b>	IgG

## Applications

### The Abpromise guarantee

Our **Abpromise guarantee** covers the use of ab109372 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application	Abreviews	Notes
WB	★★★★★ (1)	1/1000 - 1/10000. Detects a band of approximately 145 kDa (predicted molecular weight: 92 kDa).
IP		1/10 - 1/100.

### Application notes

Is unsuitable for Flow Cyt, ICC/IF or IHC-P.

## Target

### Function

Receptor for acidic and basic fibroblast growth factors.

### Involvement in disease

Defects in FGFR2 are the cause of Crouzon syndrome (CS) [MIM:123500]; also called craniofacial dysostosis type I (CFD1). CS is an autosomal dominant syndrome characterized by craniosynostosis (premature fusion of the skull sutures), hypertelorism, exophthalmos and external strabismus, parrot-beaked nose, short upper lip, hypoplastic maxilla, and a relative mandibular prognathism.

Defects in FGFR2 are a cause of Jackson-Weiss syndrome (JWS) [MIM:123150]. JWS is an autosomal dominant craniosynostosis syndrome characterized by craniofacial abnormalities and abnormality of the feet: broad great toes with medial deviation and tarsal-metatarsal coalescence.

Defects in FGFR2 are a cause of Apert syndrome (APRS) [MIM:101200]; also known as acrocephalosyndactyly type 1 (ACS1). APRS is a syndrome characterized by facio-cranio-synostosis, osseous and membranous syndactyly of the four extremities, and midface hypoplasia. The craniosynostosis is bicoronal and results in acrocephaly of brachysphenocephalic type. Syndactyly of the fingers and toes may be total (mitten hands and sock feet) or partial affecting the second, third, and fourth digits. Intellectual deficit is frequent and often severe, usually being associated with cerebral malformations.

Defects in FGFR2 are a cause of Pfeiffer syndrome (PS) [MIM:101600]; also known as acrocephalosyndactyly type V (ACS5). PS is characterized by craniosynostosis (premature fusion of the skull sutures) with deviation and enlargement of the thumbs and great toes, brachymesophalangy, with phalangeal ankylosis and a varying degree of soft tissue syndactyly. Three subtypes of Pfeiffer syndrome have been described: mild autosomal dominant form (type 1); cloverleaf skull, elbow ankylosis, early death, sporadic (type 2); craniosynostosis, early demise, sporadic (type 3).

Defects in FGFR2 are the cause of Beare-Stevenson cutis gyrata syndrome (BSCGS) [MIM:123790]. BSCGS is an autosomal dominant condition is characterized by the furrowed skin disorder of cutis gyrata, acanthosis nigricans, craniosynostosis, craniofacial dysmorphism, digital anomalies, umbilical and anogenital abnormalities and early death.

Defects in FGFR2 are the cause of familial scaphocephaly syndrome (FSPC) [MIM:609579]; also known as scaphocephaly with maxillary retrusion and mental retardation. FSPC is an autosomal dominant craniosynostosis syndrome characterized by scaphocephaly, macrocephaly, hypertelorism, maxillary retrusion, and mild intellectual disability. Scaphocephaly is the most common of the craniosynostosis conditions and is characterized by a long, narrow head. It is due to premature fusion of the sagittal suture or from external deformation.

Defects in FGFR2 are a cause of lacrimo-auriculo-dento-digital syndrome (LADDs) [MIM:149730]; also known as Levy-Hollister syndrome. LADDs is a form of ectodermal dysplasia, a heterogeneous group of disorders due to abnormal development of two or more ectodermal structures. LADDs is an autosomal dominant syndrome characterized by aplastic/hypoplastic lacrimal and salivary glands and ducts, cup-shaped ears, hearing loss, hypodontia and enamel hypoplasia, and distal limb segments anomalies. In addition to these cardinal features, facial dysmorphism, malformations of the kidney and respiratory system and abnormal genitalia have been reported. Craniosynostosis and severe syndactyly are not observed.

Defects in FGFR2 are the cause of Antley-Bixler syndrome (ABS) [MIM:207410]. ABS is a multiple congenital anomaly syndrome characterized by craniosynostosis, radiohumeral synostosis, midface hypoplasia, malformed ears, arachnodactyly and multiple joint contractures. ABS is a heterogeneous disorder and occurs with and without abnormal genitalia in both sexes.

## Sequence similarities

Belongs to the protein kinase superfamily. Tyr protein kinase family. Fibroblast growth factor receptor subfamily.


Contains 3 Ig-like C2-type (immunoglobulin-like) domains.

Contains 1 protein kinase domain.

## Cellular localization

Secreted and Cell membrane.

## Images



**Lane 1:** Wild-type HAP1 cell lysate (20 µg)

**Lane 2:** FGFR2 knockout HAP1 cell lysate (20 µg)


**Lane 3:** HeLa cell lysate (20 µg)

**Lane 4:** Jurkat cell lysate (20 µg)

**Lanes 1 - 4:** Merged signal (red and green). Green - ab109372 observed at 160 kDa. Red - loading control, [ab8245](#), observed at 37 kDa.

ab109372 was shown to specifically react with FGFR2 when FGFR2 knockout samples were used. Wild-type and FGFR2 knockout samples were subjected to SDS-PAGE.

Ab109372 and [ab8245](#) (loading control to GAPDH) were diluted at 1/1000 and 1/10,000 dilution respectively and incubated overnight at 4°C. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ([ab216773](#)) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed ([ab216776](#)) secondary antibodies at 1/10,000 dilution for 1 hour at room temperature before imaging.



Western blot - Anti-FGFR2 antibody [EPR5180] (ab109372)

**All lanes :** Anti-FGFR2 antibody [EPR5180] (ab109372) at 1/1000 dilution

**Lane 1 :** MCF7 cell lysate

**Lane 2 :** Jurkat cell lysate

**Lane 3 :** HeLa cell lysate


**Lane 4 :** K562 cell lysate

**Lane 5 :** T47-D cell lysate

Lysates/proteins at 10 µg per lane.

**Predicted band size:** 92 kDa

**Observed band size:** 145 kDa



Immunoprecipitation - Anti-FGFR2 antibody [EPR5180] (ab109372)

Purified ab109372 at 1/40 dilution (2µg) immunoprecipitating FGFR2 in T-47D whole cell lysate.

Lane 1 (input): T-47D (Human ductal breast epithelial tumor epithelial cell) whole cell lysate 10µg

Lane 2 (+): ab109372 + T-47D whole cell lysate.

Lane 3 (-): Rabbit monoclonal IgG (**ab172730**) instead of ab109372 in T-47D whole cell lysate.

VeriBlot for IP Detection Reagent (HRP) (**ab131366**) (1/1000 dilution) was used for Western blotting.

Blocking Buffer and concentration: 5% NFDm/TBST.

Diluting buffer and concentration: 5% NFDm/TBST.

Observed band size: 145 kDa

### Why choose a recombinant antibody?



**Research with confidence**  
Consistent and reproducible results



**Long-term and scalable supply**  
Recombinant technology



**Success from the first experiment**  
Confirmed specificity



**Ethical standards compliant**  
Animal-free production

Anti-FGFR2 antibody [EPR5180] (ab109372)

**Please note:** All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"

### Our Abpromise to you: Quality guaranteed and expert technical support

---

- Replacement or refund for products not performing as stated on the datasheet
- Valid for 12 months from date of delivery
- Response to your inquiry within 24 hours
- We provide support in Chinese, English, French, German, Japanese and Spanish
- Extensive multi-media technical resources to help you
- We investigate all quality concerns to ensure our products perform to the highest standards

If the product does not perform as described on this datasheet, we will offer a refund or replacement. For full details of the Abpromise, please visit <https://www.abcam.com/abpromise> or contact our technical team.

### Terms and conditions

---

- Guarantee only valid for products bought direct from Abcam or one of our authorized distributors